Companies › Renovion
1 active drug program in 1 registered trial: 1 Phase 3; Respiratory; next expected readout Feb 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ARINA-1 Nebulized mixture of ascorbic acid and reduced glutathione with immunomodulatory propertie | – | Phase 3 | Pre-Bronchiolitis Obliterans Syndrome | Feb 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05654922 | ARINA-1 | Phase 3 | Pre-Bronchiolitis Obliterans Syndrome | Respiratory | Feb 2028 |
No annotated target.
–
Biotest Areteia Therapeutics PureTech Youssef Yammine Kringle Pharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.